Morgan Stanley’s Annovis Bio ANVS Stock Holding History
Bought
Maintained
Sold
Other funds holding ANVS
VCM
VFT
MFG
Morgan Stanley's ANVS Position: Q1 2026 in Review
Morgan Stanley reduced its Annovis Bio (ANVS) stake by 42% in Q1 2026, selling an estimated $11.4K and leaving 5,733 shares worth $12.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6877.
Morgan Stanley first reported a position in ANVS in Q3 2020 and has held it in 22 quarters since. The position peaked at $2.72M in Q4 2021. 56 funds tracked by Wall St. Rank hold ANVS as of Q1 2026.
- Morgan Stanley held 5,733 shares of Annovis Bio worth $12.8K as of Q1 2026.
- Morgan Stanley sold 4,168 Annovis Bio shares in Q1 2026, an estimated $11.4K.
- Annovis Bio made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6877 holding.
- Morgan Stanley first reported a position in Annovis Bio in Q3 2020 and has held it in 22 quarters since.
- Morgan Stanley's Annovis Bio position peaked at $2.72M in Q4 2021.
- 56 funds tracked by Wall St. Rank held Annovis Bio as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.